Pharmaceutical Products Companies By Ps Ratio

Price To Sales
Price To SalesEfficiencyMarket RiskExp Return
1DSGN Design Therapeutics
22.64 K
(0.08)
 5.98 
(0.50)
2DNLI Denali Therapeutics
3.64 K
(0.12)
 4.56 
(0.56)
3NWBO Northwest Biotherapeutics
858.96
(0.06)
 3.55 
(0.21)
4SEPN Septerna, Common Stock
586.6
(0.21)
 8.96 
(1.85)
5MCRB Seres Therapeutics
390.27
(0.04)
 5.25 
(0.20)
6MREO Mereo BioPharma Group
367.7
(0.19)
 3.57 
(0.69)
7MESO Mesoblast
310.69
(0.07)
 4.52 
(0.31)
8UPB Upstream Bio,
184.56
(0.25)
 6.10 
(1.52)
9NEUP Neuphoria Therapeutics
145.56
 0.12 
 6.13 
 0.71 
10DNTH Dianthus Therapeutics
94.24
(0.05)
 4.99 
(0.24)
11MRUS Merus BV
84.99
 0.05 
 2.68 
 0.13 
12MNOV MediciNova
82.89
(0.18)
 2.88 
(0.53)
13MIST Milestone Pharmaceuticals
77.32
 0.01 
 5.40 
 0.03 
14GELS Gelteq Limited Ordinary
73.1
(0.18)
 6.23 
(1.15)
15MDGL Madrigal Pharmaceuticals
42.46
 0.05 
 4.32 
 0.20 
16MOLN Molecular Partners AG
28.79
(0.06)
 4.35 
(0.25)
17MGTX MeiraGTx Holdings PLC
17.13
 0.10 
 4.96 
 0.49 
18VERV Verve Therapeutics
14.83
(0.01)
 5.59 
(0.03)
19DYAI Dyadic International
12.14
(0.14)
 4.09 
(0.56)
20VCEL Vericel Corp Ord
9.81
(0.12)
 2.58 
(0.32)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries. The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.